Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Down 8.6 %

EVGN opened at $4.99 on Monday. The stock has a market cap of $20.56 million, a PE ratio of -10.85 and a beta of 1.40. The business has a 50 day moving average of $6.44 and a 200-day moving average of $7.26. Evogene has a 52 week low of $4.50 and a 52 week high of $11.00.

Evogene (NASDAQ:EVGN) last released its earnings results on Thursday, May 23rd. The biotechnology company reported ($0.80) EPS for the quarter. The firm had revenue of $4.19 million during the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned about 0.22% of Evogene worth $69,000 at the end of the most recent quarter. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.